Condition (MeSH)
Postmortem Changes
ClinicalTrials.gov lists 2 trials for Postmortem Changes or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
5 sections measured, none recorded · 1 not measured yet · 1 not computed
2 of the 2 trials are tagged with Postmortem Changes itself; the rest are tagged with a narrower condition beneath it.
When did Postmortem Changes trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2021 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Postmortem Changes trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Not applicable | 2 |
How many Postmortem Changes trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Postmortem Changes? (42)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia. | Cell reports | 2019 | Yes |
| Post-mortem cerebral magnetic resonance imaging T1 and T2 in fetuses, newborns and infants. | European journal of radiology | 2012 | Yes |
| Postmortem imaging of blood and its characteristics using MSCT and MRI. | International journal of legal medicine | 2006 | Yes |
| The relation of atherosclerotic lesions to antemortem and postmortem lipid levels: the Bogalusa Heart Study. | Atherosclerosis | 1993 | Yes |
| Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. | The Journal of experimental medicine | 2021 | No |
Showing 5 of 42 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.